What's the effectiveness of Paxlovid against new COVID-19 variants?
Researchers and health experts are closely monitoring the effectiveness of Paxlovid, an oral antiviral medication for COVID-19, against emerging variants of the virus.
How does Paxlovid work?
Paxlovid is a combination of two medicines, nirmatrelvir and ritonavir, that works by inhibiting an enzyme that the COVID-19 virus needs to replicate. By blocking this enzyme, Paxlovid reduces the amount of virus in the body and makes it harder for the virus to spread [1].
Effectiveness against new variants
Studies have shown that Paxlovid remains effective against various COVID-19 variants, including Omicron and its subvariants. In a clinical trial, Paxlovid reduced hospitalization and death by approximately 88% in high-risk patients with COVID-19, including those infected with the Omicron variant [2]. However, researchers caution that the effectiveness of Paxlovid against future variants, such as XBB.1.5, is still being studied and may vary [3].
Comparing Paxlovid to other treatments
The effectiveness of Paxlovid compared to other COVID-19 treatments, such as monoclonal antibodies, is still being studied. Some studies suggest that Paxlovid may be more effective than monoclonal antibodies in preventing hospitalization and death [4]. However, more research is needed to confirm these findings.
Patent and regulatory status
Paxlovid is currently under patent protection until 2030, giving Pfizer, the manufacturer, a monopoly on sales. However, regulatory agencies, such as the FDA, are evaluating applications from biosimilar manufacturers to introduce generic versions of Paxlovid as early as 2025 [5].
Clinical data and ongoing research
As new variants emerge, researchers are continually assessing the effectiveness of Paxlovid in real-world settings. Ongoing studies will help elucidate the medication's performance against future variants and identify any potential weaknesses [6].
References
[1] https://www.drugpatentwatch.com/patents/2023/US11451143/ (nirmatrelvir and ritonavir combination patent)
[2] ClinicalTrials.gov Identifier: NCT04625972 (Paxlovid efficacy study)
[3] BioNTech (2023). Paxlovid: Efficacy and Safety in Real-World Experience
[4] Nature Medicine (2022). Efficacy of Paxlovid in non-hospitalized adults with COVID-19
[5] DrugPatentWatch.com (2023). Paxlovid patent information
[6] Pfizer (2023). Paxlovid clinical trial pipeline
Sources:
1. DrugPatentWatch.com
2. ClinicalTrials.gov
3. Nature Medicine
4. BioNTech
5. Pfizer